VeraBIND™ Tau – a simple blood test for the early detection of Alzheimer’s

News

Stay up to date with the latest announcements, research highlights, and company milestones from Veravas, a diagnostics company advancing early detection technologies.

NewsVeravas, Inc. joins national accelerator to advance heart and brain health

August 12, 2025

NewsNew Research Validating VeraBIND™ Tau Assay as Accurate Blood Test for Active Tau Pathology in Alzheimer’s Disease Presented at the 2025 Alzheimer’s Association International Conference

July 28, 2025

NewsVeravas Launches VeraBIND™ Tau – First Blood Test to Detect Alzheimer’s-Related Tau Pathology

April 22, 2025

NewsVeravas Improves Diagnostic Tests by Purifying Samples

December 5, 2024

NewsVeravas Completes Analytical Verification Study of the VeraBIND Tau Assay, a Groundbreaking Test to Measure Alzheimer’s Tau Pathology in Blood

November 20, 2024

NewsVeraBIND Tau is being developed jointly with Veravas, Inc. and Phanes Biotech, Inc.

November 7, 2024